Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients (RP_MPR)
A Multicenter, Open Label Study Of Oral Revlimid And Prednisone (Rp) Followed By Oral Revlimid Melphalan And Prednisone (Mpr) In Newly Diagnosed Elderly Multiple Myeloma Patients
Sponsor: Fondazione EMN Italy Onlus
A PHASE2 clinical study on Multiple Myeloma, this trial is completed. The trial is conducted by Fondazione EMN Italy Onlus and has accumulated 12 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2022 — Jul 2023 [monthly]
Active Not Recruiting PHASE2
-
Feb 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Jul 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fondazione EMN Italy Onlus
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.